

References

- **Abbadie C., Lindia J. A., Cumiskey A. M., Peterson L. B., Mudgett J. S., Bayne E. K., DeMartino J. A., MacIntyre D. E., Forrest M. J. (2003):** Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. *National Academy of Science U.S.A.*, 100: 7947–7952.
- **Adriana R. B., Rocksane C. N., Márcia B. R., Ennio L., Mendes P. R. (2007):** C-reactive protein as an indicator of low intensity inflammation in children and adolescents with and without obesity. *Journal de Pediatria.*, 83(5): 477-480.
- **Aeberli I., Biebinger R., Lehmann R., Allemann D., Giatgen A. S., Zimmermann M. B. (2007):** Serum retinol-binding protein 4 concentrations and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. *The Journal of Clinical Endocrinology & Metabolism.*, 92(11): 4359–4365.
- **Alaniz M., Helena F., Takada J., Cardoso A. V., Lima B. F. (2007):** Adipose tissue as an endocrine organ: from theory to practice. *Journal de Pediatria.*, 83(5): S192-S203.
- **Alessi M and Juhan I (2008):** Metabolic syndrome, haemostasis and thrombosis. *Thromb Haemost*; 99: 995-1000.
- **Alessi M. C., Peiretti F., Morange P., Henry M., Nalbone G., Juhan V. (1997):** Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. *Diabetes.*, 46(5): 860-867.

- **Alessi, M.C., Poggi, M., Juhan-Vague, I.(2007)** : Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. *Curr. Opin. Lipidol.* 18, 240–245.
- **Al-Hazimi A. (2004):** Relationship between Arterial Blood Pressure, Angiotensin 2 and leptin. *Egypt Journal of Medical Laboratory Science.*, (13).
- **Allison M, John P and Douglas L (2005):** Treatment of the Metabolic Syndrome: The Impact of Lifestyle Modification. *Current Atherosclerosis Reports*; 7:95 –102
- **Ana Azevedo A, Paulo B and Pedro B (2007):** Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities-cross-sectional study of the general population. *BMC Cardiovascular Disorders*; 7: 17-25.
- **Andrew J. W., Blakemore I. A., Froguel P. (2006):** Genetics of obesity and the prediction of risk for health. *Human Molecular Genetics.*, 15(2): R124–R130.
- **Apovian, C.M., Bigornia, S., Mott, M., Meyers, M.R., Ulloor, J., Gagua, M., McDonnell,M., Hess, D., Joseph, L., Gokce, N., (2008):** Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. *Arterioscler. Thromb. Vasc. Biol.* 28, 1654–1659.
- **Arbeeny C.; Sacchiero R. and Booker M. (2001):**The metabolic syndrome: from pathophysiology to novel treatment strategies.
- **Aruna D. P., Manson E. J., Rifai N., Buring J. E., Ridker P. M. (2001):** C-reactive protein, interleukin 6, and risk of developing

type 2 diabetes mellitus. Journal of the American Medical Association., 286: 327-334.

- **Assman G.; Schriewer H.; Schmitz G. and Hagele E.O. (1983):** Quantification of high density lipoprotein cholesterol by precipitation with phosphotungestic acid/MgC₁₂. Clin. Chem.. 29: 2026-2027.
- **Bacha F, Rola S and Neslihan G (2003):** Obesity, Regional Fat Distribution, and Syndrome X in Obese Black Versus White Adolescents: Race Differential in Diabetogenic and Atherogenic Risk Factors. J Clin Endocrinol Metab; 88(6):2534-40
- **Bacha F., Saad R., Gungor N., Arslanian S. (2006):** Are obesity-related metabolic risk factors modulated by the degree of insulin resistance in adolescents? Diabetes Care., 29: 1599-1604.
- **Baggiolini M, Loetscher P. (2000):** Chemokines in inflammation and immunity. Immunol Today 2000;21:418–20.
- **Banks W. A., Coon B. A., Robinson M. S., Moinuddin A., Shultz M. J., Nakaoke R., Morley E. J. (2004):** Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes., 53: 1253-1260.
- **Barrett J. R. (1997):** Chemokines. Blood., 90: 909-928.
- **Bastard, J.P., Lagathu, C., Caron, M., Capeau, J. (2007) :** Point-counterpoint: interleukin- 6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102, 821–822.

- **Bastelica, D., Morange, P., Berthet, B., Borghi, H., Lacroix, O., Grino, M., Juhan-Vague, I., Alessi, M.C., (2002):** Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between viscera and subcutaneous deposits. *Arterioscler. Thromb. Vasc. Biol.* 22, 173–178.
- **Bates O. D. (2003):** The role of vascular endothelial growth factor in wound healing. *The International Journal of Lower Extremity Wounds.*, 2(2): 107-120.
- **Becker L. C. (2005):** Yin and Yang of MCP-1. *Circulation Research.*, 96: 812-815.
- **Bermudez E. A., Rifai N., Buring J., Manson J. E., Ridker P. M. (2002):** Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. *Arteriosclerosis Thrombosis and Vascular Biology.*, 22: 1668-73.
- **Boucher J., Masri B., Daviaud D. (2005):** Apelin, a newly identified adipokine up-regulated by insulin and obesity. *Endocrinology.* , 146: 1764-1771.
- **Bourlier, V., Zakaroff-Girard, A., Miranville, A., De Barros, S., Maumus, M., Sengenès, C., Galitzky, J., Lafontan, M., Karpe, F., Frayn, K.N., Bouloumie, A. (2008) :** Remodeling phenotype of human subcutaneous adipose tissue macrophages. *Circulation* 117, 806–815.

- **Brendt J., Kling N., Kralish C. (2005):** Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. *Diabetes.*, 54: 2911-2916.

- **Bruun M. J., Lihn A. S., Pedersen S. B., Richelsen B.(2005):** Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. *The Journal of Clinical Endocrinology & Metabolism.*, 90(4): 2282–2289.

- **Bruun M. J., Verdich C., Toubro S., Astrup A., Richelsen B. (2003):** Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor- α effect of weight loss in obese men. *European Journal of Endocrinology*, 148: 535–542.

- **Bruun, J.M., Lihn, A.S., Verdich, C., Pedersen, S.B., Toubro, S., Astrup, A., Richelsen, B. (2003) :**Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. *Am. J. Physiol. Endocrinol. Metab.* 285, E527–E533.

- **Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr(1999):** Body-mass index and mortality in a prospective cohort of US adults. *N Engl J Med*341 :1097 –1105.

- **Cancello, R., Henegar, C., Viguerie, N., Taleb, S., Poitou, C., Rouault, C., Coupaye, M., Pelloux, V., Hugol, D., Bouillot, J.L., Bouloumie, A., Barbatelli, G., Cinti, S., Svensson, P.A., Barsh, G.S., Zucker, J.D., Basdevant, A., Langin, D., Clement, K. (2005) :** Reduction of macrophage infiltration and chemoattractant

gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. *Diabetes* 54, 2277–2286.

- **Carl A.; Ashwood E. R. and Bruns D.E. (2006):** Lipids, lipoproteins, apolipoproteins and other cardiovascular risk factors. In *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics*; 2: 903-967.
- **Catalán V., Gómez-Ambrosi J., Ramirez B., Rotellar F., Pastor C., Silva C., Amaia M., Gil M. J., Cienfuegos J., Frühbeck G. (2007):** Proinflammatory cytokines in obesity: Impact of type 2 diabetes mellitus and gastric bypass. *Obesity Surgery.*, 17: 1464-1474.
- **Cawthorn, W.P., Sethi, J.K.(2008):** TNF-alpha and adipocyte biology. *FEBS Lett.* 582,117–131.
- **Ceska R. (2007):** Clinical implications of the metabolic syndrome. *Diabetes and Vascular Diseases Research.* 4: S2–S4.
- **Chan W. B., Tong P. C., Chow C. C., So W. Y., Ng M. C., Ma R. C., Osaki R., Cockram C. S., Chan J. C. (2004):** Triglyceride predicts cardiovascular mortality and its relationship with glycaemia and obesity in Chinese type 2 diabetic patients. *Diabetes Metabolism Research and Review.*, 21:183-188.
- **Charles Wadsworth et al. Clinica Chimica Acta(1984):** 138: 309– 318.
- **Charo, I.F., and Taubman, M.B.(2004):** Chemokines in the pathogenesis of vascular disease. *Circ. Res.* 95:858-866.

- **Chen, A., Mumick, S., Zhang, C., et al (2005):** Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. *Obes Res.* **8**: 1311–1320.
- **Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH.(2004):** Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. *Kidney Int* ;65:116–28.
- **Chow F. Y., Nikolic-Paterson D. J., Ma F. Y., Ozols E., Rollins B. J., Tesch. G. H. (2007):** Monocyte chemoattractant protein-1 induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. *Diabetologia.*, 50:471-480.
- **Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH.(2006):** Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. *Kidney Int* ;69:73–80.
- **Christiansen T, Richelsen B & Bruun JM (2005):** Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. *International Journal of Obesity and Related Metabolic Disorders* 29 146–150.
- **Christou N. V., Sampalis J. S., Liberman M. (2004):** Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. *Annals of Surgery.*, 240: 416-23.
- **Chudek J., Wiecek A. (2005):** Adipose tissue, inflammation and endothelial Dysfunction. *Pharmacological report.*, 58: 81-89.

- **Church T. S., Willis M. S., Priest E. L., La Monte M. J., Earnest C. P., Wilkinson W. J., Wilson D. A., Giroir B. P. (2005):** Obesity, macrophage migration inhibitory factor, and weight loss. *International Journal of Obesity.*, 29: 675–681.
- **Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, A.S., Obin, M.S.(2005):** Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. *J. Lipid Res.* 46, 2347–2355.
- **Colditz IG, Schneider MA, Pruenster M, Rot(2007):** Chemokines at large: in-vivo mechanisms of their transport, presentation and clearance. *Thromb Haemost* ;97:688–93.
- **Cook D. G., Mendall M. A., Whincup P. H., Carey I. M., Ballam L., Morris J. E. (2000):** C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. *Atherosclerosis.*, 149: 139-50.
- **Cottam D. R., Schaefer P. A., Shafan G. W., Velcu L., Angus L. D. (2002b):** Effect of surgically-induced weight loss on leukocyte indicators of chronic inflammation in morbid obesity. *Obesity Surgery.*, 12: 335-342.
- **Coughlan CM, McManus CM, Sharron M, et al.(2000):** Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons. *Neuroscience* ;97:591–600.

- **Cristina B, Giuseppe B and Giuseppe D (2008):** Optimizing management of metabolic syndrome to reduce risk focus on life-style. *Intern Emerg Med*; 3:87-98.

- **Curat C. A., Miranville A., Sengenès C., Tonus C., Diehl M., Busse R., Bouloumié A. (2004):** From blood monocytes to adipose-tissue-resident macrophages: induction of diapedesis by human mature adipocytes. *Diabetes.*, 53: 1285–1292.

- **Curat C. A., Miranville A., Sengenès C., Tonus C., Wegner R. B., Bouloumié A. (2006):** Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. *Diabetologia.*, 49: 744–747.

Curr. Med. Chem. 1: 1-24.

- **Dahlman I., Kaaman M., Olsson T., Tan D.G., Bickerton S. T., Wåhlen K., Andersson J., Arvidsson N. E., Blomqvist L., Sjogren A., Forsgren M., Attersand A., Arner P. (2005):** A unique role of monocyte chemoattractant protein-1 among chemokines in adipose tissue of obese subjects. *The Journal of Clinical Endocrinology & Metabolism.*, 90(10): 5834–5840.

- **Dandona, P., Weinstock, R., Thusu, K., Abdel-Rahman, E., Aljada, A., Wadden, T. (1998):** Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. *J. Clin. Endocrinol. Metab.* 83, 2907–2910.

- **Dawson J., Wolfgang M., Anis K. M., Wiessner C. (2003):** Targeting monocyte chemoattractant protein-1 signalling in disease. *Expert Opinion on Therapeutic Targets.*, 7(1): 35-48.

- **De Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP & Braunwald E. (2003):** Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. *Circulation* 107 690–695.
- **De Mota N. and Goazigo R. L. (2004):** Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. *National Academy of Science U.S.A.*, 101: 10464-10469.
- **De Simone G, Devereux R and Chinali M (2007):** Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. *Diabetes Care*; 30 (7):1851-56.
- **Delma J. N., Cnop M., Retzlaff B., Alden E. C., Brunzell D. J., Knopp H. R., Kahn E. S. (2003):** The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. *Diabetes.*, 52: 172-179.
- **Deo R., Khera A., Darren K. M.G., Murphy S. A., Meo- Neto P. J., Morrow A. D., Lemos J. A. (2004):** Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. *Journal of American Collection of Cardiology.*, 44: 1812-1818.
- **Després J, Lemieux I and Bergeron J (2008):** Abdominal obesity and the metabolic syndrome: contribution to global cardio-metabolic risk. *Arterioscler ThrombVasc Biol*; 28(6): 1039-49.

- **Devaraj S., Kumaresan P. R., Jialal I. (2004):** Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. *Journal of Molecular and Cellular Cardiology.*, 36: 405-410.
- **Devaraj S., Xu D. Y., Jialal I. (2003):** C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. *Circulation*, 107: 398–404.
- **Dietschy J.M.; Weeks L.E. and Delento J.J. (1976):** Enzymatic assessment of free and estrified cholesterol levels using the oxygen electrode in a modified glucose analyzer. *Clin. Chem.. Acta*; 73: 407.
- **Dilek T., Ozelsancak R., Turan I., Micozkadiglu H., Sezer S., Ozdemir F. (2007):** The relationship between obesity and transforming growth factor beta on renal damage in essential hypertension. *International Heart Journal*, 48(6):733-741.
- **Distler J. H. W., Akhmetshina A., Schett A., Distler O. (2009):** Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. *Rheumatology*, 48(2): 98-103.
- **Dixon J. B., Paul E., O' Brien R. (2006):** Obesity and the white blood cell count: Changes with Sustained Weight Loss. *Obesity Surgery*, 16: 251-257.
- **Eastham RD. (1985):** *Biochemical Values in Clinical Medicine*, 7th ED Bristol , England, Ltd, 18,313-326.

- **Eckardstein A., Nofer J. R., Assmann G. (2001):** High density lipoproteins and arteriosclerosis. *Arteriosclerosis Thrombosis and Vascular Biology.*, 21:13-27.
- **Eckel R. H., Grundy S. M., Paul Z. Z. (2005):** The metabolic syndrome. *Lancet.*, 365: 1415-1428.
- **Eliot A (2008):** Does the Addition of Fibrates to Statin Therapy Have a Favorable Risk to Benefit Ratio? *Current Atherosclerosis Reports*; 10:25-32.
- **Engeli, S., Schling, P., Gorzelniak, K., Boschmann, M., Janke, J., Ailhaud, G., Teboul, M., Massiera, F., Sharma, A.M. (2003):** The adipose-tissue rennin–angiotensin– aldosterone system: role in the metabolic syndrome? *Int. J. Biochem. Cell Biol.* 35, 807–825.
- **Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R. & Giugliano D. (2003):** Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women. *Journal of the American Medical Association* ., 289: 1799–1804.
- **Fain, J.N., Bahouth, S.W., Madan, A.K.(2004) :** TNFalpha release by the nonfat cells of human adipose tissue. *Int. J. Obes. Relat. Metab. Disord.* 28, 616–622.
- **Fan J, Heller NM, Gorospe M, Atasoy U, Stellato C.(2005):** The role of post-transcriptional regulation in chemokine gene expression in inflammation and allergy. *Eur Respir J* ;26:933–4.
- **Fantuzzi G. (2005):** Adipose tissue, adipokines, and inflammation. *Journal of Allergy and Clinical Immunology.*, 115: 911-919.

- **Fernandez E., Lolis E. (2002):** Structure, function, and inhibition of chemokines. *Annual Review of Pharmacology and Toxicology.*, 42: 469–499.
- **Ferri, C., Desideri, G., Valenti, M., Bellini, C., Pasin, M., Santucci, A., De Mattia, G. (1999) :** Early upregulation of endothelial adhesion molecules in obese hypertensive men. *Hypertension* 34, 568–573.
- **Festa, A., D’Agostino Jr., R., Tracy, R.P., Haffner, S.M., (2002):** Elevated levels of acute phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. *Diabetes* 51,1131–1137.
- **Flegal KM, Carroll MD, Ogden CL, Johnson CL(2002):** Prevalence and trends in obesity among US adults, 1999–2000. *JAMA*288 :1723 –1727.
- **Fontana, L., Eagon, J.C., Trujillo, M.E., Scherer, P.E., Klein, S., (2007):** Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. *Diabetes* 56, 1010–1013.
- **Ford E, Giles W and Dietz W (2002):** Prevalence of metabolic syndrome among U.S. adults: Findings from the third National Health and Nutrition Examination Survey. *JAMA*; 287:356-59.
- **Ford ES, Giles WH, Mokdad AH(2008):** Increasing prevalence of the metabolic syndrome among U.S. adults. *Diabetes Care*27 :2444 –2449.
- **Formiguera X. and Canton A. (2005):** Obesity, epidemiology and clinical aspects. *Best Pract. Res. Clin. Gastroenterol* 18 (6): 1125-1146.

- **Fortes, J.G. Mendes, A. Stinghen, M.C. Riella and R. Pecoits-Filho (2007):** Metabolic Syndrome Is Associated with Increased Plasma Levels of Monocyte Chemoattractant Protein in Dialysis Patients. *Perit Dial Int* 27;3: 12.
- **Frangogiannis N., Dewald O., Xia Y., Guofeng R., Haudek S., Leucker T. K., Taffet D., Rollins G., Barrett J., Entman M. L.(2007):** Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. *Circulation.*, 115(5): 584-592.
- **Fridlender ZG, Kapoor V, Buchlis G, et al.(2010):** CCL2 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. *Am J Respir*
- **Fried, S.K., Bunkin, D.A., Greenberg, A.S. (1998):** Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. *J. Clin. Endocrinol. Metab.* 83, 847–850.
- **Friedwald W.T.; Levy R.I. and Fridrickson D.S. (1972):** Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifugation. *Clin. Chem.*. 18: 449-501.
- **Fukami, H. Adachi, M. Enomoto, S. Kumagae, M. Otsuka, Y. Shigetoh, K. Furuki, A. Satoh, T. Imaizumi.(2007):** The association between serum monocyte chemoattractant protein-1(MCP-1) and the metabolic syndrome. *Obesity/Metabolic syndrome 76th Congress of the European Atherosclerosis Society* . 21,630 -171.

- **Fukuhara A., Matsuda M., Nishizawa M. (2005):** Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. *Science.*, 307: 426-430.
- **Furukawa S.; Fujita T. and Shimabukuro M. (2004):** Increased oxidative stress in obesity and its impact on metabolic syndrome. *J. Clin. Invest.* 114 (12): 1752-1761.
- **Galassi A, Reynolds K, He J(2006):** Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. *Am J Med*119 :812 – 819.
- **Gerard C, Rollins BJ. (2001):**Chemokines and disease.*Nat Immunol* ;2:108–15.
- **Giacchetti, G., Faloia, E., Sardu, C., Camilloni, M.A., Mariniello, B., Gatti, C., Garrapa,G.G., Guerrieri, M., Mantero, F.(2000):** Gene expression of angiotensinogen in adipose tissue of obese patients. *Int. J. Obes. Relat. Metab. Disord.* 24 (Suppl. 2), S142–S143.
- **Giunti S, Pinach S, Arnaldi L, et al.(2006):** The MCP-1/CCR2 system has direct proinflammatory effects in human mesangial cells. *Kidney Int* ;69:856–63.
- **Giuseppe M., Hammarstedt A., Madele S., Schmelz M., Herder C., Smith U., Jansson P. A. (2007):** Monocyte chemoattractant protein-1 in subcutaneous abdominal adipose tissue: characterization of interstitial concentration and regulation of gene expression by insulin. *The Journal of Clinical Endocrinology and Metabolism.*, 92(7): 2688–2695.

- **Gokalp D., Alpaslan T., Hatice A., Senay A., Mithat B. (2007):** The association of high sensitivity C-reactive protein levels with body fat mass and body fat distribution. *European Society of Endocrinology.*, 14: 238- 244.
- **Goran I, Bergman N and Cruz L (2002):** Insulin resistance and associated compensatory responses in african-american and Hispanic children. *Diabetes care*; 25 (12): 2184-90.
- **Gordon S., Taylor P. R. (2005):** Monocyte and macrophage heterogeneity. *National Review of Immunology.*, 5: 953–964.
- **Gottschling-Zeller, H., Birgel, M., Rohrig, K., Hauner, H., (2000):** Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. *Metabolism* 49, 666–671.
- **Greenfield J. R., Samaras K., Jenkins A. B., Kelly P. J., Spector T. D., Gallimore J. R., Pepys M. B., Campbell L. V. (2004):** Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. *Circulation.*, 109: 3022–3028.
- **Gregory S, Cohn M and Roger S (2005):** Toward an Improved Diagnosis of the Metabolic Syndrome: Other Clues to the Presence of Insulin Resistance. *American Journal of Hypertension*; 18 (8) 1099-03.
- **Grewal IS, Rutledge BJ, Fiorillo JA, et al. (1997):** Transgenic Monocyte Chemoattractant Protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes. Abrogation by

- a second transgene expressing systemic MCP-1. *J Immunol* ;159:401–8.
- **Gruden G, Setti G, Hayward A, et al.(2005):** Mechanical stretch induces monocyte chemoattractant activity via an NF-kappa B-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. *J Am Soc Nephrol* ;16:688–96.
 - **Gu L, Hagiwara S, Fan Q, et al.(2006):** Role of receptor for advanced glycation endproducts and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. *Nephrol Dial Transplant* ;21:299–313.
 - **Gu L, Tseng SC, Rollins BJ.(1999):** Monocyte Chemoattractant Protein-1. *Chem Immunol*;72:7–29.
 - **Gu, L., Okada, Y., Clinton, S.K., Gerard, C., Sukhova, G.K., Libby, P., Rollins, B.J.(1998):** Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. *Mol. Cell* 2, 275–281.
 - **Guerre-Millo, M.(2004) :** Adipose tissue and adipokines: for better or worse. *Diabetes Metab.* 30, 13–19.
 - **Guzik T. J., Mangalat D., Korbout R. (2006):** Adipocytokines a novel link between inflammation and vascular function. *Journal of Physiology and Pharmacology.*, 57(4): 505-528.
 - **Haider G. D., Schindler K., Schaller G., Prager G., Wolzt M., Ludvik B. (2006):** Increased plasma visfatin concentrations in

morbidly obese subjects are reduced after gastric banding. The Journal of Clinical Endocrinology & Metabolism., 91(4): 1578–1581.

- **Hajime K., Sanshiro T., Yoshikazu T., Kotani K., Hiasa K., Kitazawa R., Kitazawa S., Miyachi H., Maeda S., Egashira K., Kasuga M. (2006):** MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. Journal of Clinical Investigation., 116(6): 1494-1505.
- **Hamsten A., De Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., Blombäck M., Wiman B. (1987):** Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet., 2: 3-9.
- **Hanusch-Enserer U., Cauza M., Spak E., Dunky A., Rosen H. R., Prager R., Wolf H., Eibl M. M. (2003):** Acute phase response and immunological markers in morbid obese patients and patients following adjustable gastric banding. International Journal of Obesity., 27: 355-361.
- **Harman-Boehm, I., Bluher, M., Redel, H., Sion-Vardy, N., Ovadia, S., Avinoach, E. Shai, I., Kloting, N., Stumvoll, M., Bashan, N., Rudich, A., (2007):** Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J. Clin. Endocrinol. Metab. 92, 2240–2247.
- **Hartner A, Veelken R, Wittmann M, Cordasic N, Hilgers KF.(2005):** Effects of diabetes and hypertension on macrophage

infiltration and matrix expansion in the rat kidney. BMC Nephrol ;6:6.

- **Hasan T and Ertan Y (2006)** : Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome? International Journal of Cardiology; 110: 276 -77.
- **Heinonen M. V., Purhonen A. K., Miettinen P. (2005)**: Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regulatory Peptides., 130: 7-13.
- **Henegar, C., Tordjman, J., Achard, V., Lacasa, D., Cremer, I., Guerre-Millo, M., Poitou, C., Basdevant, A., Stich, V., Viguerie, N., Langin, D., Bedossa, P., Zucker, J.D., Clement, K.(2008)**: Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol. 9, R14.
- **Henrike and Jürgen (2007)**: Monocyte chemotactic protein-1 and its role in insulin resistance. Current Opinion in Lipidology. Lipid metabolism ; 18 - 3- 258-262.
- **Herder C., Scholze S. M., Rating P., Koenig W., Thorand B., Haastert B., Holle R., Illig T., Rathmann W., Seissler J., Wichmann E., Kolb H. (2006)**: Systemic monocyte chemoattractant protein-1 concentrations are independent of type 2 diabetes or parameters of obesity: results from the cooperative health research in the region of augsburg survey S4 (KORA S4). European Journal of Endocrinology., 154: 311–317.

- **Hidekuni I. (2008):** The usefulness of circulating adipokine levels for the assessment of obesity-related health problems. *International Journal of Medical Sciences.*, 5(5):248-262.
- **Hong KH, Ryu J, Han KH.(2005) :** Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. *Blood* 105:1405–7.
- **Hotamisligil, G.S., Shargill, N.S., Spiegelman, B.M.(1993) :** Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. *Science* 259, 87–91.
- **Hsieh S. D., Yoshinaga H., Muto T. (2003):** Waist-to-height ratio, a simple and practical index for assessing central fat distribution and metabolic risk in Japanese men and women. *International Journal of Obesity.*, 27: 610–616.
- **Imagawa Y., Yamaguchi K., Ogawa N., Obara N., Suzuki M., Yamamoto M., Nagasawa T. (2004):** Interleukin-6 and tumor necrosis factor- α in patients with obstructive sleep apnea-hypopnea syndrome. *International Journal of Thoracic Medicine.*, 71: 24-29.
- **Iwasaki T., Nakajima A., Yoneda M., Terauchi Y. (2006):** Relationship between the serum concentrations of C-reactive protein and parameters of adiposity and insulin resistance in patients with type 2 diabetes mellitus. *Endocrine journal.*, 53: 345-356.
- **Jager J., ThierryG., Cormont M., Yannick M. P., Tanti F. (2007):** Interleukin-1 β -induced insulin resistance in adipocytes through down-regulation of Insulin Receptor Substrate-1 Expression.*Endocrinology.*, 148(1): 241–251.

- **Jernas, M., Palming, J., Sjöholm, K., Jennische, E., Svensson, P.A., Gabrielsson, B.G., Levin, M., Sjögren, A., Rudemo, M., Lystig, T.C., Carlsson, B., Carlsson, L.M., Lonn, M.(2006) :** Separation of human adipocytes by size hypertrophic fat cells display distinct gene expression. *FASEB J.* 20,1540–1542.
- **John N. Fain (2010) :** Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells *Obesity Research* .;513948, 20.
- **Jung H., Toth P. T., Fletcher A. W., Miller R. J. (2008):** Monocyte chemoattractant protein-1 functions as a neuromodulator in the dorsal root ganglia neurons. *Journal of Neurochemistry.*, 104(1): 254–263.
- **Kadowaki H., Yamauchi T. (2005):** Adiponectin and adiponectin receptors. *Endocrine Review.*, 26: 439-451.
- **Kantarzis K., Ritting K., Ballet Shofer B. (2006):** The relationship of plasma adiponectin with a favorable lipid profile. *Clinical Chemistry.*, 52: 1934-1942.
- **Kasuga, M. ,Park, H.S., Kawada, T., Kim, J.H., Lim, D., Hubbard, N.E., Kwon, BS., Kim Erickson, KL., and Yu, R.(2006):** Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. *Int. J. Obes (Lond).* 30:1347-1355.
- **Kato S, Luyckx VA, Ots M, et al.(1999) :** Renin–angiotensin blockade lowers MCP-1 in diabeteus. *Kidney Int* ;56:1037–48.

- **Kelley D. and Mandarino L. (2000) :** Fuel selection in human skeletal muscle in insulin resistance: a reexamination. *Diabetes* 49: 677 - 683.
- **Kim C. S., Park H. S., Kawada T., Kim J. H., Lim D., Hubbard N. E., Kwon B. S., Erickson K. L., Yu R. (2006):** Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity related parameters. *International Journal of Obesity.*, 30: 1347–1355.
- **Klok M. D., Jakobsdottir S., Drent M. L. (2007):** The role of leptin and ghrelin in the regulation of food intake and body weight in humans. *Obesity reviews.*, 8(1): 21-34.
- **Koenig W, Sund M, Frohlich M et al.(1999):** C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. *Circulation.* 99:237–242.
- **Kolovo F, Genovefa D and Katherine K (2007) :** The prevalence of metabolic syndrome in various populations. *American Journal of the Medical Sciences*; 333(6):362-71.
- **Kwang K, Seung H and Michael J (2005) :** Inflammatory Markers and the Metabolic Syndrome Insights From Therapeutic Interventions. *Journal of the American College of Cardiology*; 4: 6: 1978-85.
- **Lam D. C. L., Xu A., Lam K. S. L., Lam B., Lam J. C. M., Lui M. S., Ip M. S. M. (2009):** Serum adipocyte-fatty acid binding

protein level is elevated in severe obstructive sleep apnea and correlates with insulin resistance. *European Respiratory Journal.*, 33: 346-351.

- **Lau D. C. W., Dhillon B., Yan H., Szmitk P. E., Verma S. (2005):** Adipokines: molecular links between obesity and atherosclerosis. *American Journal of Physiology.*, 288: H2031–H2041.
- **Leandro S. G., García B. H., Pita J., Nieves D. G., Genoveva D. C., Rovira A. (2008):** High-sensitivity C-reactive protein is a good marker of cardiovascular risk in obese children and adolescents. *European Journal of Endocrinology.* 159(1): R1-R4.
- **Lebovitz H. E. (2001):** Insulin resistance: definition and consequences. *Clinical Endocrinology and Diabetes.*, 109 (2): 135-148.
- **Lemieux I., Agnès P., Prud'homme D., Alméras N., Bogaty P., Nadeau A., Bergeron J., Després J. P. (2001):** Elevated C-reactive protein another component of the atherothrombotic profile of abdominal obesity. *Arteriosclerosis Thrombosis and Vascular Biology.*, 21:961-967.
- **Lequin R (2005):** Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). *Clin. Chem.* **51** (12): 2415–8. doi:10.1373/clinchem.051532. PMID 16179424.
- **Ligia J, Dominguez M and James R (2005):** Metabolic Syndrome Therapy: Prevention of Vascular Injury by Antidiabetic Agents. *Current Hypertension Reports*; 7:110 -16.

- **Lijnen, H.R., Alessi, M.C., Van Hoef, B., Collen, D., Juhan-Vague, I., (2005) :** On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. *J. Thromb. Haemost.* 3, 1174–1179.

- **Lijnen, H.R., Maquoi, E., Morange, P., Voros, G., Van Hoef, B., Kopp, F., Collen, D., Juhan-Vague, I., Alessi, M.C. (2003):** :Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. *Arterioscler. Thromb. Vasc. Biol.* 23, 78–84.

- **Lin Y., Lee H., Berg A. H., Lisanti M. P., Shapiro L., Scherer P. E. (2000):** The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. *Journal of Biological Chemistry.*, 275: 24255–24263.

- **Linda V. D., David P. R. (2007):** Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. *Endocrine-Related Cancer Journal.*, 14: 189–206.

- **Lionel H. O. (2007):** Metabolic syndrome. *Circulation.*, 23:32-35.

- **Lombard L., Augustyn M. N., Ascott-Evans B. H. (2002):** The metabolic syndrome pathogenesis, clinical features and management. *Cardiovascular Journal of South Africa.*, 13(4): 181-186.

- **Long J. R., Liu P. Y., Liu Y. J., Lu Y., Xiong D. H., Elze L., Recker R. R., Deng HW. (2003):** APOE and TGF-b1 genes are associated with obesity phenotypes. *Journal of Medical Genetics.*, 40: 918–924.

- **Lu S. C., Shieh W. Y., Chen C. Y., Hsu S. C., Chen H. L. (2002):** Lipopolysaccharide increases resistin gene expression in vivo and in vitro. *FEBS Letter.*, 530: 158-162.
- **Lumeng, C.N., Bodzin, J.L., Saltiel, A.R.(2007) :** Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *J. Clin. Invest.* 117, 175–184.
- **Lumeng, C.N., DelProposto, J.B., Westcott, D.J., Saltiel, A.R. (2008):** Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. *Diabetes* 57, 3239–3246.
- **Lundien MC, Mohammed KA, Nasreen N, et al.(2002):** Induction of MCP-1 expression in airway epithelial cells: role of CCR2 receptor in airway epithelial injury. *J Clin Immunol* ;22:144–52.
- **Ma, L.J., Mao, S.L., Taylor, K.L., Kanjanabuch, T., Guan, Y., Zhang, Y., Brown, N.J., Swift, L.L., McGuinness, O.P., Wasserman, D.H., Vaughan, D.E., Fogo, A.B.(2004) :** Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.*Diabetes* 53, 336–346.
- **Mainous G, King E and Garr R (2004) :** Race, rural residence, and control of diabetes and hypertension. *Ann Fam Med*; 2(6):563-68.
- **Makoto N., Toshiki M., Yoshiro S., Keiko Y. T. (2007):** Abdominal obesity exhibits distinct effect on inflammatory and anti-inflammatory proteins in apparently healthy Japanese men. *Cardiovascular Diabetology.*, 6: 27-31.

- **Malavazos A., Cereda E., Morricone L., Coman C., Ambrosi B. (2005):** Monocyte chemoattractant protien-1 a possible link between visceral adipose tissue- associated inflammation and subclinical echocardiographic abnormalities in uncomplicated obesity. *European Journal of Echocrinology.*, 153:871-877.
- **Malnick S. D. H., Knobler H. (2006):** Complications of obesity. *Oxford Journal of Medicine.*, 99: 565–579.
- **Mankowska A., Sypniewska G. (2006):** New adipokines linked to obesity and obesity-related diseases. *International Federation of Clinical Chemistry and Laboratory Medicine.*, 17(4): 231-239.
- **Marti A., Marcos A., Martinez A. (2001):** Obesity and immune function relationship. *The International Association for The Study of Obesity.*, 2:131-140.
- **Martinovic I., Abegunewrdene N., Seul M., Vosseler M., Horstic G., Buerke M., Darius H., Lindemann S. (2005):** Elevated monocyte chemoattractant protien-1 serum levels in patients at risk for coronary artery disease. *Circulation Journal.*, 69:1484-1489.
- **Massiera, F., Bloch-Faure, M., Ceiler, D., Murakami, K., Fukamizu, A., Gasc, J.M.,Quignard-Boulange, A., Negrel, R., Ailhaud, G., Seydoux, J., Meneton, P., Teboul,M.(2001):** Adipose angiotensinogen is involved in adipose tissue growth andblood pressure regulation. *FASEB J.* 15, 2727–2729.
- **Mataix J., Magdalena L. F., Pilar A., Lopis J. (2005):** Factors associated with obesity in an adult mediterranean population:

influence on plasma lipid profile. *Journal of the American College of Nutrition.*, 24(6): 456–465.

- **Matilde R. Chacón, José Manuel Fernández-Real, Cristóbal Richart, Ana Megía, José Manuel Gómez, Merce Miranda, Enric Caubet, Rosa Pastor, Carles Masdevall, Núria Vilarrasa, Wifredo Ricard and Joan Vendrell (2007):** Monocyte Chemoattractant Protein-1 in Obesity and Type 2 Diabetes. *Insulin Sensitivity Study International Journal of Obesity*; 15, 664–672
- **Matter M., Handschin C. (2007):** Inflammation, obesity and the metabolic syndrome. *Circulation.*, 115: 946-948.
- **Maury, E., Ehala-Aleksejev, K., Guiot, Y., Detry, R., Vandenhooft, A., Brichard, S.M.(2007) :** Adipokines oversecreted by omental adipose tissue in human obesity *Am. J. Physiol. Endocrinol. Metab.* 293, E656–E665.
- **Maury, E., Ehala-Aleksejev, K., Guiot, Y., Detry, R., Vandenhooft, A., Brichard, S.M.(2007):** Adipokines oversecreted by omental adipose tissue in human obesity. *Am. J. Physiol. Endocrinol. Metab.* 293, E656–E665.
- **Maury, E., Noel, L., Detry, R., Brichard, S.M. (2009):** In vitro hyper-responsiveness to TNF- α contributes to adipokine dysregulation in omental adipocytes of obese subjects. *J. Clin. Endocrinol. Metab.*.
- **Mc Ternan P. G., Kusminski C. M., Kumar S. (2006):** Resistin. *Current Opinion in Lipidology.*, 17:170-175.

- **McGowan M.W.; Artiss J.D. and Strodborgh D.R. (1983):**A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin. Chem.. 29: 273-278.
- **Mine, S., Okada, Y., Tanikawa, T., Kawahara, C., Tabata, T., and Tanaka Y.(2008):** Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem. Biophys. Res. Commun. 344:780-785.
- **Miranda P. J.;DeFronzo R.A.; Califf R.M. and Guyton J. (2005):** Metabolic syndrome: Definition, pathophysiology and mechanisms.Am. Heart J 149: 33-45.
- **Mitchell M., Armstrong D. T., Robker R. L., Norman R. J. (2005):** Adipokines: implications for female fertility and obesity. The Journal of the Society for Reproduction and Fertility., 130: 583-597.
- **Mohanty P., Aljada A., Ghanim H. (2004):** Evidence for a potent anti-inflammatory effect of rosiglitazone. Journal of Clinical Endocrinology and Metabolism., 89: 2728–2735.
- **Moser B, Loetscher P.(2001):** Lymphocyte traffic control by chemokines. Nat Immunol 2001;2:123–8.
- **Mundy GR, Boyce B, Hughes D, et al(1995):** The effects of cytokines and growth factors on osteoblastic cells. Bone ;17:71S–5S.
- **Nakazawa T., Toshio H., Chifuyu N., Kosuke N., Kazuichi M., Haicheng S., Matsubara A., Miyahara S., Shintaro N., Yuqin Y., Benowitz L., Moghadam H. A., Miller J. W. (2007):**

Monocyte chemoattractant protein 1 mediates retinal detachment-induced photoreceptor apoptosis. The National Academy of Sciences of the U.S.A., 104(7): 2425-2430.

- **National Cholesterol Education Program (NCEP)(2002):** Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. *Circulation* 106:3143–3421.
- **Nieman C. D., Henson A. D., Nehlsen L. S., Ekkens M., Utter C. A., Butterworth E. D., Fagoaga R. O. (1999):** Influence of obesity on immune function. *Journal of the American diabetic association.*, 99(3): 294-299.
- **Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A and Chen RS (2004):** Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. *Circulation*; 109:42- 6.
- **Niu J, Azfer A, Zhelyabovska O, Fatma S, Kolattukudy PE.(2008):** Monocyte Chemotactic Protein (MCP)-1 Promotes Angiogenesis via a Novel Transcription Factor, MCP-1-induced Protein (MCPIP). *J Biol Chem* ;283:14542–51.
- **Noto H, Chitkara P and Raskin P (2006):** The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. *J Diabetes Complications*; 20 (6):343-48.

- **Nozomu K., Kazuyuki T., Ryo S., Mitsuru O., Taku W., Naoto K., Norie O. K., Katsuyoshi K., Kentaro S., Masatoshi K., Toshimasa Y., Kohjiro U., Yumiko O., Satoshi N., Ichiro M., Haruo H., Yasuyuki O., Hitomi O., Kumpei T., Masaki T., Tomohiro I., Koji M., Ryozo N., Takashi K. (2006):** Over expression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. *Journal of Biological Chemistry.*, 281(36): 26602-26614.
- **Nuria Barbarroja¹, Rosario López-Pedrerá, María Dolores Mayas, Eduardo García-Fuentes, Lourdes Garrido-Sánchez, Macías-González, Rajaa El Bekay, Antonio Vidal- Francisco, J. Tinahones (2010) :** *Biochem. J.* 430 (141–149).
- **O’Dea K., Walker K., Colagiuri S., Hepburn A., Holt P., Colagiuri R. (2002):** Evidence based guidelines for type 2 diabetes mellitus. *National English Journal of Medicine.*, 346: 393-403.
- **Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, (2006):** Prevalence of overweight and obesity in the united states, 1999–2004. *JAMA* 295 :1549 –1555.
- **Ohashi, K., Kihara, S., Ouchi, N., Kumada, M., Fujita, K., Hiuge, A., Hibuse, T., Ryo, M., Nishizawa, H., Maeda, N., Maeda, K., Shibata, R., Walsh, K., Funahashi, T., Shimomura, I.(2006) :** Adiponectin replenishment ameliorates obesity-related hypertension. *Hypertension* 47, 1108–1116.
- **Ohta, H., Wada, H., Niwa, T., Kirii, H., Iwamoto, N., Fujii, H., Saito, K., Sekikawa, K., Seishima, M.(2005) :** Disruption of tumor necrosis factor-alpha gene diminishes the development of

- atherosclerosis in ApoE-deficient mice. *Atherosclerosis* 180, 11–17.
- **Olufadi R and Byrne C (2008):** Clinical and laboratory diagnosis of the metabolic syndrome. *J Clin. Pathol*; 61:697-706.
 - **Omata N., Motoko Y., Akiko Y., Hiromichi I., Mitsufumi M., Yusei O. (2002):** Monocyte chemoattractant protein-1 selectively inhibits the acquisition of CD40 ligand-dependent IL-12-producing capacity of monocyte-derived dendritic cells and modulates Th1 immune response. *Journal of Immunology.*, 169: 4861-4866.
 - **Park H. S., Park J. Y., Yu R. (2005):** Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF alpha and IL-6. *Diabetes Research and Clinical Practice.*, 69: 29-35..
 - **Pepys M. B., Hirschfield G. M. (2003):** C-reactive protein: a critical update. *Journal of Clinincal Investigation.*, 111: 1805–1812.
 - **Petrkova J., Szotkowska, J., Hermanova Z., Lukl J., Petrek M. (2004):** Monocyte chemoattractant protein-1 in patients with peripheral arterial disease. *Mediators of Inflammation.*, 13(1): 39-43.
 - **Phillippa J, Miranda M and Ralph A (2005):** Metabolic syndrome: Definition, patho-physiology, and mechanisms. *American Heart Journal*; 149 (1) 33-45.
 - **Plomgaard, P., Bouzakri, K., Krogh-Madsen, R., Mittendorfer, B., Zierath, J.R., Pedersen, B.K.(2005) :** Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human

subjects via inhibition of Akt substrate 160 phosphorylation. *Diabetes* 54, 2939–2945.

- **Pollex R. L., Ban R. M., T Kue Y., Bjerregaard Peter, Anand S. S., Salim Y., Bernard Z., Harris B. S., Hanley J. G., Connelly W. P., Huff W. M., Hegele A. R. (2007):** Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample. *BMC Medical Genetics*, 8:80-87.
- **Proost P, Wuyts A, Van Damme J. (1998):** Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. *J Leukoc Biol* 1996;59:67–74.
- **Qiao Q, Gao W and Zhang L (2007):** Metabolic syndrome and cardiovascular disease. *Ann Clin Biochem*; 44: (3):232-63.
- **Quignard-Boulange, A., Negrel, R., Ailhaud, G., Seydoux, J., Meneton, P., Teboul, M. (2001) :** Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. *FASEB J.* 15, 2727–2729.
- **Rexford S. A. (2006):** Adipose tissue as an endocrine gland. *Obesity.*, 14: 242s-249s.
- **Ridker PM. (2001):** High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. *Circulation.* 103:1813–1818.
- **Rifai N., Ridker P. M. (2001):** High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease. *Clinical Chemistry.*, 47(3): 403–411.

- **Robert S. (2008):** Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. *American Heart Journal*; 155(3): 499-515.
- **Robinson M., Michaela S. F., Leeson P., Channon K. M., Kieran C., Neubauer S., Wiesmann F. (2008):** Uncomplicated obesity is associated with abnormal aortic function assessed by cardiovascular magnetic resonance. *Journal of Cardiovascular Magnetic Resonance.*, 10: 10-18.
- **Ruan, H., Hachohen, N., Golub, T.R., Van Parijs, L., Lodish, H.F.(2002):** Tumor necrosisfactor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. *Diabetes* 51, 1319–1336.
- **Ryu S. Y., Kweon S., Park H., Shin J., Jung R. (2007):** Obesity and the metabolic syndrome in Korean adolescents. *Journal of Korean Medical Science.*, 22: 513-517.
- **Ryu S. Y., Young S. L., Jong P., Myeng Geun K., Kim S. (2005):** Relations of Plasma High- Sensitivity C- reactive protein to Various Cardiovascular Risk Factors. *Journal of Korean Medical Sciences.*, 20: 379-383.
- **Salcedo R., Ponce M. L., Young H. A. (2000):** Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. *Blood.*, 96: 34–40.

- **Sardo M. A., Campo S., Mandraffino G., Saitta C., Bonaiuto A., Castaldo M., Cinquegrani M., Pizzimenti G., Saitta A. (2008):** Tissue factor and monocyte chemoattractant protein-1 expression in hypertensive individuals with normal or increased carotid intima-media wall thickness. *Journal of Clinical Chemistry*, 54(5): 814-823.
- **Sartipy, P., Loskutoff, D.J. (2003):** Monocyte chemoattractant protein 1 in obesity and insulin resistance. *Proc. Natl. Acad. Sci. U.S.A.* 100, 7265–7270.
- **Sassy-Prigent C, Heudes D, Mandet C, et al.(2000):** Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. *Diabetes* ;49:466–75.
- **Schall TJ, Bacon KB (1994) :** Chemokines, leukocyte trafficking, and inflammation. *Curr Opin Immunol* ;6:865–73.
- **Schaller A. F., Dean V. (2008):** Addressing overweight and obesity: evolving to a medical consensus. *The Journal of the American Osteopathic Association*, 108 (2): 2-15.
- **Scheen, A.J.(2004):** Renin–angiotensin system inhibition prevents type 2 diabetesmellitus. Part 1. A meta-analysis of randomised clinical trials. *Diabetes Metab.*30, 487–496.
- **Schernthaner G. H., Kopp H. P., Kriwanek S., Katarzyna K., Satler M., Koppensteiner R., Schernthaner G. (2006):** Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractant-protein-1 in morbid obesity. *Obesity Surgery*, 16: 709-715.

- **Schneider A, Panzer U, Zahner G, et al. (1999) :** Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor- β . *Kidney Int* ;56:135–44.

- **Schneider J. H., Glaesmer H., Klotsche J., Lehnert H., Andreas M. Z., Winfried M., Pittrow D., Günter K. S., Wittchen H. U. (2006):** Accuracy of anthropometric indicators of obesity to predict cardiovascular risk. *The Journal of Clinical Endocrinology & Metabolism.*, 92(2): 589-594.

- **Schulze M., Grim E., Shai I. (2004):** Relationship between adiponectin and glycemic control, blood lipids and inflammatory markers in men with type 2 diabetes. *Diabetes Care*, 27: 1680-1687.

- **Schutte A, Rooyen J and Huisman H (2003):** Factor analysis of possible risks for hyper-tension in a black South African population. *Journal of Human Hypertension*; 17: 339-48.

- **Schweickart VL, Epp A, Raport CJ, Gray PW. (2000) :** CCR11 is a functional receptor for the monocyte chemoattractant protein family of chemokines. *J Biol Chem* ;275: 9550–6.

- **Sell H., Eckel J. (2007):** Monocyte chemotactic protein-1 and its role in insulin resistance. *Current Opinion in Lipidology*, 18: 258–262.

- **Sengenès, C., Miranville, A., Lolmede, K., Curat, C.A., Bouloumie, A., (2007) :** The role of endothelial cells in inflamed adipose tissue. *J. Intern. Med.* 262, 415–421.

- **Seung H, Michael J and Jeong K (2007)** : Adiponectin and Cardiovascular Disease Response to Therapeutic Interventions. *Journal of the American College of Cardiology*; 49(5): 531-38.
- **Sheikine Y, Hansson GK. (2004): Chemokines and atherosclerosis.** *Ann Med* 2004;36: 98–118.
- **Shirai K. (2004):** Obesity as the core of the metabolic syndrome and the management of coronary heart disease. *Curr med Res Opin*; 20 (3): 295-304.
- **Shoelson, S.E., Herrero, L., Naaz, A. (2007)** : Obesity, inflammation, and insulin resistance. *Gastroenterology* 132, 2169–2180.
- **Shoelson, S.E., Lee, J., Goldfine, A.B.(2006)** : Inflammation and insulin resistance. *J. Clin. Invest.* 116, 1793–1801.
- **Shulman GI(2000):** Cellular mechanisms of insulin resistance. *J Clin Invest*106 :171 –176.
- **Shyy YJ, Hsieh HJ, Usami S, Chien S. (1994):**Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 gene expression in vascular endothelium. *Proc Natl Acad Sci U S A* ;91:4678–8.
- **Sierra-Johnson J. and Johnson B.D. (2004)** : Facial fat and its relationship to abdominal fat, a marker for insulin resistance.*Med. Hypotheses* 63 (5): 783-786.
- **Silswal N., Singh A. K., Aruna B., Mukhopadhyay S., Ghosh S., Ehtesham N. Z. (2005):** Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by

NF-kappaB-dependant pathway. *Biochemistry Research Community*, 334(4): 1092-1101.

- **Silventoinen K, Sans S, Tolonen H, Monterde D, Kuulasmaa K, Kesteloot H, Tuomilehto J; WHO MONICA Project(2004):** Trends in obesity and energy supply in the WHO MONICA project. *Int J Obes Relat Metab Disord* 28 :710 –718.

- **Simeoni E., Hoffmann M. M., Winkelmann B. R., Ruiz J., Fleury S., Boehm B., März W., Vassalli G. (2004):** Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. *Diabetologia*, 47: 1574–1580.

- **Simin L., Manson E. J., Buring E. J., Stampfer J. M., Willett C. W., Ridker M. P. (2002):** Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. *The American Journal of Clinical Nutrition*, 75: 492–498.

- **Skoog, T., Dichtl, W., Boquist, S., Skoglund-Andersson, C., Karpe, F., Tang, R., Bond, M.G., de Faire, U., Nilsson, J., Eriksson, P., Hamsten, A., (2002):** Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. *Eur. Heart J.* 23, 376–383.

- **Skurk T., Herder C., Kräfft B I., Scholze M. S., Hauner H., Kolb H. (2004):** Production and release of macrophage migration inhibitory factor from human adipocytes. *Endocrinology*, 146(3): 1006-1011.

- **Snodgrass J. J., William R. L., Tarskaia A. L., McDade W. T., Sorensen V. M., Alekseev P. V., Krivoschapkin G. V. (2007):** Anthropometric correlates of C- reactive protein among indigenous Siberians. *Journal of Physiological Anthropology*, 26: 241–246.

- **Sonnenberg E. G., Glenn R. K., Martin J. L., Olivier M., Kwitek E. A., Comuzzie G. A. , Blangero J., Kissebah H. A. (2004):** Genetic determinants of obesity-related lipid traits. *Journal of Lipid Research*, 45: 610-615.

- **Sozzani S, Locati M, Zhou D, et al. (2000) :** Receptors, signal transduction, and spectrum of action of monocytechemotactic protein-1 and related chemokines. *J Leukocyte Biol* ;57:788–94

- **Spalding, K.L., Arner, E., Westermark, P.O., Bernard, S., Buchholz, B.A., Bergmann, O., Blomqvist, L., Hoffstedt, J., Naslund, E., Britton, T., Concha, H., Hassan, M., Ryden, M., Frisen, J., Arner, P.(2008):** Dynamics of fat cell turnover in humans. *Nature* 453, 783–787.

- **Steppan C. M., Bailey S. T., Bhat S., Brown E. J., Banerjee R. R., Wright C. M., Patel H. R., Ahima R. S., Lazar M. A. (2001):** The hormone resistin links obesity to diabetes. *Nature.*, 409: 307-312.

- **Strackowski M., Strackowska D. S., Agnieszka S., Kowalska I., Malgorzata S., Kinalska I. (2002):** Plasma Interleukin-8 Concentrations Are Increased in Obese Subjects and Related to Fat Mass and Tumor Necrosis Factor- α System. *The Journal of Clinical Endocrinology and Metabolism*, 87(10): 4602–4606.

- **Stumvoll M (2002):** Reduced lipolysis as possible cause for greater weight gain in subjects with the Pro12Ala polymorphism in PPARgamma2? *Diabetologia*; 45 (1):152-53.

- **Sun J. H., Yang B., Donnelly D. F., Ma C., Lamotte R. H. (2006):** MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia. *Journal of Neurophysiology*, 96: 2189–2199.

- **Sung S. H., Chuang S. Y., Wayne H. H. S., Lee W. J., Pesus C., Chen H. C. (2008):** Adiponectin, but not leptin or high-sensitivity C- reactive protein, is associated with blood pressure independently of general and abdominal adiposity. *Hypertension Research*, 31(4): 633-640.

- **Takahashi K., Mizuarai S., Araki H., Mashiko S., Ishihara A., Kanatani A., Itadani H., Kotani H. (2003):** Adiposity elevates plasma MCP-1 levels leading to the Increased CD11b-positive Monocytes in Mice. *The Journal of Biological Chemistry.*, 278(47): 46654–46660.

- **Takahashi, N., Li, F., Hua, K., Deng, J., Wang, C.H., Bowers, R.R., Bartness, T.J., Kim, H.S., Harp, J.B.(2007) :** Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. *Cell Metab.* 6, 506–512.

- **Tavil Y, Sen N, Yazici HU and Hizal F (2007):** Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. *Thrombosis Research*; 120: 245-250.

- **Thelen M. (2001) :** Dancing to the tune of chemokines. *Nat Immunol* ;2:129–34.

- **Theodore W. K., Gerald F. W., Hugh R. B., Kerry A. R., Chan C. D. (2007):** Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome. *Diabetes Care.*, 30: 2945-2950.

- **Tilg H., Moschen A. R. (2006):** Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *National Review of Immunology.*, 6: 772-783.

- **Timothy A. W., Satvinder S. D., Stanley A. B. (2003):** Waist–hip ratio is the dominant risk factor predicting cardiovascular death in Australia. *Medical Journal of Australia.*, 179: 580-585.

- **Tretjakovsab, Antra Jurkaab, Inga Bormanea, Vitolds Mackevics, Indra Mikelsona, Liga Balodea, Dace Reihmanea, Inga Stukenac, Guntis Bahsc, Juris Imants Aivarsa, Valdis Piragsb (2009) :** Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients., *Diabetes and Vascular Diseases Research* 20, I 7, 712.

- **Troseid M, Lappegard KT, Claudi T, Damas JK, Morkrid L, Brendberg R & Mollnes TE(2004):**Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. *European Heart Journal* 25 349.

- **Tso A. W. K., Aimin X., Pak C. S., Nelson M. S. W., Yu W., Fong H. Y. A., Bernard M. Y. C., Edward D. J., Karen S. L. L. (2007):** Serum adipocyte fatty acid–binding protein as a new biomarker predicting the development of type 2 diabetes; A 10-year prospective study in a Chinese cohort . *Diabetes Care.*, 30: 2667-2672.

- **Uysal K. T., Scheja L., Wiesbrock S. M., Bonner-Weir S., Hotamisligil G. S. (2000):** Improved glucose and lipid metabolism in genetically obese mice lacking aP2. *Endocrinology.*, 141: 3388-3396.
- **Valente AJ, Xie JF, Abramova MA, Wenzel UO, Abboud HE, Graves DT. (1998) :** A complex element regulates IFN-stimulated monocyte chemoattractant protein-1 gene transcription. *J Immunol* ;161:3719–28.
- **Van Coillie E, Van Damme J, Opdenakker G. (1999) :** The MCP/eotaxin subfamily of CC chemokines. *Cytokine Growth Factor Rev* 1999;10:61–86.
- **Van Harmelen, V., Ariapart, P., Hoffstedt, J., Lundkvist, I., Bringman, S., Arner, P.(2000):**Increased adipose angiotensinogen gene expression in human obesity.*Obes. Res.* 8, 337–341.
- **Vasan R. S. (2003):** Cardiac function and obesity. *Heart.*, 89: 1127-1129.
- **Vasudevan A. R., Wu M., Xydakis A. M., Jones P. H. (2006):** Eotaxin and obesity. *Journal of Clinical Endocrinology and Metabolism.*, 91: 256-261.
- **Verma S., Li S. H., Wang C. H., Fedak P. W., Li R. K., Weisel R. D., Mickle D. A. (2003):** Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. *Circulation.*, 108(6): 736-740.
- **Viedt C, Vogel J, Athanasiou T, et al. (2002):** Monocyte Chemoattractant Protein-1 induces proliferation and interleukin-6

production in human smooth muscle cells by differential activation of nuclear factor-B and activator protein-1. *Arterioscler Thromb Vasc Biol* ;22:914–20.

- **Vishwa D. D. (2008):** Adipose-immune interactions during obesity and caloric restriction: reciprocal mechanisms regulating immunity and health span. *Journal of Leukocyte Biology.*, 84:189-200.
- **Wada T, Yokoyama H, Furuichi K, et al.(2001):** Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor MCAF/MCP- 1. *FASEB J* ;10:1418–25.
- **Wada T, Yokoyama H, Matsushima K, Kobayashi K.(2001):** Chemokines in renal diseases. *Int Immunopharmacol* 2001;1:637–45.
- **Wagner W, Roderburg C, Wein F, et al(2007):** Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. *Stem Cells* ;25:2638–47.
- **Walley A. J., Blakemore I. F. A. and Frogue P. (2006):** Genetics of obesity and the prediction of risk for health. *Human Molecular Genetics.*, 15(2): R124–R130.
- **Wang SN, La Page J, Hirschberg R.(2000):** Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. *Kidney Int* ;57:1002–14.
- **Wang TJ, Nam BH and D’Agostino RB (2003):** Carotid intima-media thickness is associated with premature parental coronary

heart disease: the Framingham Heart Study. *Circulation*; 108: 572-76.

- **Wang, B., Wood, I.S., Trayhurn, P.(2007) :** Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. *Pflugers Arch.* 455, 479–492.
- **Wang, Z.V., Scherer, P.E.(2008) :** Adiponectin, cardiovascular function, and hypertension. *Hypertension* 51, 8–14
- **Warnberg J., Esther N., Moreno L. A., Javier R., Mesana M. I., Ruiz J. R., Ortega F. P., Sjöström M., Manuel B., Ascensión M. (2006):** Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population. *American Journal of Clinical Nutrition.*, 84: 505–512.
- **Warnick G.R.; Knopp R.H. and Fitzpatrick V. (1990):** Estimating low density lipoprotein cholesterol by the friedwald equation is adequate for classifying patients on the basis of nationally recommended cut points. *Clin. Chem.* 36: 15-17.
- **Weber KS, Nelson PJ, Grone HJ, Weber C.(1999):** Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and in vivo inflammatory activation of endothelium. *Arterioscler Thromb Vasc Biol* ;19:2085–93.
- **Weili Y., Bingxian H., Yao H., Jianghong D., Cui J., Dongliang G., Zheng Y., Ling L., Yanying G., Xiao K., Xiaohai F., Ma D. (2007):** Waist-to-height ratio is an accurate and easier index for evaluating Obesity in Children and Adolescents. *Obesity.*, 15(3):748-752.

- **Weisberg S. P., Mc-Cann D., Desai M., Rosenbaum M., Leibel R. L., Ferrante A.W. (2003):** Obesity is associated with macrophage accumulation in adipose tissue. *Journal of Clinical Investigation*.112: 1796–1808.
- **Weisberg, S. P., Hunter, D., Huber, R., et al (2006) :** CCR2 modulates inflammatory and metabolic effects of high-fat feeding. *J Clin Invest*. **1**: 115–124.
- **Wellen, K. E., Hotamisligil, SG. (2003):** Obesity-induced inflammatory changes in adipose tissue. *J Clin Invest*. **112**: 1785–178.
- **Weyer C.; Foley J. and Bogardus C.(2000):** Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. *Diabetologia* 43: 1498 - 1506.
- **William S. L., Cummings E. D. (2005):** Regulation of ghrelin in physiologic and pathophysiologic states. *The Journal of Nutrition*., 135(5): 1320 1325.
- **Wisse BE(2004):** The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity. *J Am Soc Nephrol*15 :2792 –2800.
- **Womack J., Tien C. P., Feldman J., Shin H. J., Fennie K., Anastos K., Cohen M. K., Bacon C. M., Minkoff H. (2007):** Obesity and Immune Cell Counts in Women. *Metabolism*., 56(7): 998–1004.

- **Xia Y, Frangogiannis NG. (2007):** MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy. *Inflamm Allergy Drug Targets* ;6:101–7.
- **Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., Chen, H.(2003):**Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J. Clin. Invest.* 112,1821–1830.
- **Yamagishi S, Inagaki Y, Okamoto T, et al.(2002):** Advanced glycation end productinduced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human cultured mesangial cells. *J Biol Chem* ;277:20309–15.
- **Yen H, Zhang Y, Penfold S, Rollins BJ.(1997):** MCP-1-mediated chemotaxis requires activation of non-overlapping signal transduction pathways. *J Leukocyte Biol* 1997;61:529–32.
- **Yihai C. (2007):** Angiogenesis modulates adipogenesis and obesity. *The Journal of Clinical Investigation.*, 117: 2362-2368.
- **Yoshimura T, Robinson EA, Tanaka S, Appella E, Leonard EJ.(1999):** Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. *J Immunol* ;142:1956–62.
- **Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ.(1999):**Human Monocyte Chemoattractant Protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-

stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett ;244:487–93.

- **Yu X, Dluz S, Graves DT, et al.(1992):** Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci U S A ;89:6953–7.
- **Yuji T., Kazuo M., Fumio U. (2005):** High-Sensitivity C - reactive protein in Japanese Patients with Type 2 Diabetes. Obesity Research., 13(10): 1810-1816.
- **Yvan-Charvet, L., Massiera, F., Lamande, N., Ailhaud, G., Teboul, M., Moustaid- Moussa, N., Gasc, J.M., Quignard-Boulangue, A.(2009):** Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology 150, 1421–1428.
- **Zhang, K., Kaufman, R.J.(2008) :** From endoplasmic-reticulum stress to the inflammatory response. Nature 454, 455–462.
- **Zineh I., Beitelshes L. A., Silverstein H. J., Haller J. M. (2009):** Serum monocyte chemoattractant protein-1 concentrations associate with diabetes status but not arterial stiffness in children with type 1 diabetes. Diabetes Care., 32: 465-467.
- **Zlotnik A, Yoshie O, Nomiyama H(2006):** The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol ;7:243.
- **Zoccali C., Mallamaci F., Tripepi G. (2003):** Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney International Journal., 84: S65–S68.